The drug Xarelto (rivaroxaban), manufactured by Bayer and Johnson & Johnson subsidiary, Jannsen Pharmaceuticals, was approved by the US Food and Drug Administration (FDA) in July of 2011. Xarelto is often referred to as a blood thinner. Xarelto belongs in a class of drugs known as direct thrombin inhibitors, anticoaquiants.
Xarelto is a new-generation anticoagulant prescription medicine that was designed to have three main uses, to:* reduce the risk of blood clots and stroke in patients with atrial fibrillation
Xarelto alters the normal blood clotting of the blood in the human body. Clotting is a necessary component when a human is injured from an open wound, however, some people the clotting process happens when they are not injured.
Blood clots occurring in the legs (deep vein thrombosis - DVT) and pulmonary embolism (blood clots in the lungs) can and may cause serious complications and/or possible death if left untreated.
There is a heart condition known as Atrial fibrillation which is characterized by an irregular heartbeat causing blood to pool in the heart and may lead to clots. If this type of blood clot flows to the brain, they may cause a stroke.
Unfortunately, Xarelto (Rivaroxaban) has Side Effects* Excessive Bleeding
Recently, Xarelto has been reportedly linked to an increased risk of uncontrollable bleeding which is referred to as hemorrhaging. Hemorrhaging exists in many blood thinners.
Prior to Xarelto a prescription known as warfarin (known to consumers by the brand name Coumadin) was used which has an antidote, vitamin K, to reduce the risk of uncontrollable hemorrhaging. Some of the newer blood thinners do not have an antidote. This means people using Xarelto who gets an injury, including minor cuts and/or internal bleeding, can result in uncontrolled bleeding, which can be fatal. Xarelto was marketed as a better prescription for patients since it did not required medical monitoring like prior medicines.
Unfortunately Xarelto is proving to be less than desirable with having 151 deaths associated with Xarelto in 2012 and 2,081 serious adverse events in the same year. As more Xarelto patents and family members come forward with their nightmare stories of Xarelto usage, the serious adverse events and deaths continue to grow in numbers.
Xarelto and Pradaxa (another anticoagulant medication approved by FDA in 2010) are both anticoagulants that do not have an antidote, meaning they could potentially cause the patient to have uncontrollable bleeding.
As statistics continue to accumulate against the use of Xarelto, the drug Pradaxa, manufacturer Boehringer Ingelheim, recently settled some of their legal issues with 4,000 legal cases against Pradaxa being paid approximately $650 million.
Xarelto users, like Pradaxa users, are the subject of lawsuits filed against their makers for failing to warn about the lack of an antidote to the drugs which cause serious injuries and deaths to some of the consumers.
If you, a loved one or someone you know has experienced serious complications or death from taking Pradaxa, you may be entitled to compensation.
A free, no-obligation consultation is available to see if you have a case and entitled to a cash compensation.